Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)

Summary

Background

Latent autoimmune diabetes of adulthood (LADA) differs in clinical features from type 2 diabetes. Whether this difference translates into different risks of complications remains controversial. We examined the long-term risk of microvascular complications in people enrolled in the UK Prospective Diabetes Study (UKPDS), according to their diabetes autoimmunity status.

Methods

We did a post-hoc analysis of 30-year follow-up data from UKPDS (UKPDS 86). UKPDS participants with diabetes autoantibody measurements available and without previous microvascular events were included. Participants with at least one detectable autoantibody were identified as having latent autoimmune diabetes, and those who tested negative for all autoantibodies were identified as having type 2 diabetes. The incidence of the primary composite microvascular outcome (first occurrence of renal failure, renal death, blindness, vitreous haemorrhage, or retinal photocoagulation) was compared between adults with latent autoimmune diabetes and those with type 2 diabetes. The follow-up ended on Sept 30, 2007. Baseline and updated 9-year mean values of potential confounders were tested in Cox models to adjust hazard ratios (HRs). UKPDS is registered at the ISRCTN registry, 75451837.

Findings

Among the 5028 participants included, 564 had latent autoimmune diabetes and 4464 had type 2 diabetes. After median 17·3 years (IQR 12·6–20·7) of follow-up, the composite microvascular outcome occurred in 1041 (21%) participants. The incidence for the composite microvascular outcome was 15·8 (95% CI 13·4–18·7) per 1000 person-years in latent autoimmune diabetes and 14·2 (13·3–15·2) per 1000 person-years in type 2 diabetes. Adults with latent autoimmune diabetes had a lower risk of the composite outcome during the first 9 years of follow-up than those with type 2 diabetes (adjusted HR 0·45 [95% CI 0·30–0·68], p<0·0001), whereas in subsequent years their risk was higher than for those with type 2 diabetes (1·25 [1·01–1·54], p=0·047). Correcting for the higher updated 9-year mean HbA_1c seen in adults with latent autoimmune diabetes than in those with type 2 diabetes explained entirely their subsequent increased risk for the composite microvascular outcome (adjusted HR 0·99 [95% CI 0·80–1·23], p=0·93).

Interpretation

At diabetes onset, adults with latent autoimmune diabetes have a lower risk of microvascular complications followed by a later higher risk of complications than do adults with type 2 diabetes, secondary to worse glycaemic control. Implementing strict glycaemic control from the time of diagnosis could reduce the later risk of microvascular complications in adults with latent autoimmune diabetes.

Funding

European Foundation for the Study of Diabetes Mentorship Programme (AstraZeneca).

Introduction

Diabetes-related autoantibodies are detectable in 2–12% of adults with a clinical diagnosis of type 2 diabetes.1, 2, 3 These people are affected by a mild form of autoimmune diabetes known as latent autoimmune diabetes of adulthood (LADA). An overlap in the pathogenesis and clinical features of type 2 diabetes and type 1 diabetes has been hypothesised in latent autoimmune diabetes.⁴

Diabetic microvascular complications are a major cause of end-stage renal disease and blindness worldwide.5, 6 We have previously shown a similar risk of major cardiovascular events in latent autoimmune diabetes and type 2 diabetes.⁷ However, the prevalence of microvascular complications might differ among diabetes types because of different pathogenesis and prevalence of risk factors, but data in this regard are scarce. The comparative evaluation of vascular complications between different forms of diabetes could aid in risk stratification, which is essential to help promote individualised prevention of complications and treatment strategies. Furthermore, it might show crucial differences in risk factors, which could have an impact on the understanding of the pathogenesis of complications in the different forms of diabetes. In this regard, data from the Diabetes Control and Complications Trial⁸ suggested that preserved β-cell secretion of insulin is associated with lower incidence of retinopathy and nephropathy in type 1 diabetes. Differences in autoantibody concentrations also affect clinical features of patients with latent autoimmune diabetes.⁹ However, whether β-cell function and autoimmune load are linked to microvascular complications in latent autoimmune diabetes has not been determined.

Research in context

Evidence before this study

In a systematic review published in 2017, we reviewed original articles reporting the risk of complications in latent autoimmune diabetes of adulthood. Taken together, these studies suggested a lower prevalence of microvascular complications in latent autoimmune diabetes compared with type 2 diabetes in patients with short disease duration and an opposite picture in patients with longer disease duration, with uncertainties about the factors explaining this time-dependent difference. To update the evidence, we searched PubMed for articles published up to Oct 1, 2019, with the following search criteria: “latent autoimmune diabetes of the adults” or “LADA” AND “retinopathy” or “nephropathy” or “complications”. Most studies that had investigated this topic were, however, limited by small sample sizes and by heterogeneity among the individuals enrolled with respect to ethnicity, metabolic control, and disease duration. We have shown previously that the risk of cardiovascular disease does not differ between latent autoimmune diabetes and type 2 diabetes after adjusting for risk factors. Whether this is true also for microvascular complications needs to be clarified.

Added value of this study

The UK Prospective Diabetes Study has the largest population of adults with latent autoimmune diabetes, with the longest follow-up ever evaluated in a randomised clinical trial for diabetes complications. The enrolment of patients with newly diagnosed type 2 diabetes, the adjudication of hard clinical outcomes, the full availability of risk factor data measured at several timepoints, and a follow-up of up to 30 years permit a more detailed comparison of the natural history of microvascular complications in adults with latent autoimmune diabetes and those with type 2 diabetes. Our study provides insights into the association between diabetes heterogeneity and microvascular complications, showing that patients with latent autoimmune diabetes have a lower risk of developing microvascular complications over 9 years from diagnosis than do those with type 2 diabetes, and that their subsequent higher risk can be explained by their earlier worse glycaemic control.

Implications of all the available evidence

Complication risk stratification is essential to help promote individualised prevention of complications in type 2 diabetes and to inform treatment strategies. In this regard, the comparative evaluation of vascular complication risks between the different forms of diabetes is an open research area. Results of this study might allow tailored screening strategies and highlight the existence of an early therapeutic window in latent autoimmune diabetes to improve microvascular outcomes by implementing strict glycaemic control. Randomised controlled trials are needed to test the efficacy of antidiabetes therapy for improving glycaemic control and microvascular outcomes in latent autoimmune diabetes.

In this study, we aimed to evaluate the long-term risk of microvascular complications and the factors affecting this risk in latent autoimmune diabetes compared with type 2 diabetes in the large population of adults with a clinical diagnosis of new-onset type 2 diabetes enrolled in the UK Prospective Diabetes Study (UKPDS). Furthermore, we explored whether allocation to intensive, compared with conventional, glycaemic control strategies had different effects on microvascular complications in adults with latent autoimmune diabetes or type 2 diabetes.